HOME > MARKETS > COMPANY NEWS
  COMPANY NEWS
COMPANY
Alkem Laboratories launches Cetuxa
May-30-2023

Alkem Laboratories has launched Cetuxa, the world's first biosimilar of Cetuximab, used for the treatment of head and neck cancer. The introduction of the medication is in line with the company's endeavour to ensure affordability, accessibility and availability while saving the lives of critically ill cancer patients.

Cetuxa is administered as an intravenous infusion and is available as 100 mg (2 mg/mL) in a single-dose vial. In India, more than 76,000 patients are eligible for the use of cetuximab for the management of head and neck cancer. Currently, only around 1,611 patients are managed by this therapy. Its reach in India is limited partly due to its high cost. To address this issue, it has launched an affordable biosimilar, which is backed by indigenous research and production.

Alkem Laboratories is a leading Indian pharmaceutical company with global operations, engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The company produces branded generics, generic drugs, active pharmaceutical Ingredients (APIs) and nutraceuticals, which it markets in India and International markets.

  RELATED NEWS >>